This is in line with at least three independently reported phenomena: (i) ChAT is one of the few enzymes known to possess a splice variant with a nuclear localization signaling motif at its amino terminus [65], allowing it to enter the nucleus on demand; (ii) ChAT expression/activity seems to increase in the brain of patients at an early stage of Alzheimer’s disease, namely mild cognitive impairment [66], contrasting its severe reduction in the brain at later stages of AD; (iii) mitochondrial dysfunction is reported as one of the features of AD [67, 68]. Here, CHAT is linked to Alzheimer disease.